Get the Stockscreener App
5.90
5.90%
-0.37
After Hours:
5.90
Tenax Therapeutics Inc stock is traded at $5.90, with a volume of 34,459.
It is down -5.90% in the last 24 hours and down -9.79% over the past month.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
See More
Previous Close:
$6.27
Open:
$6.25
24h Volume:
34,459
Relative Volume:
0.69
Market Cap:
$20.11M
Revenue:
-
Net Income/Loss:
$-14.56M
P/E Ratio:
-0.3508
EPS:
-16.82
Net Cash Flow:
$-12.46M
1W Performance:
-16.55%
1M Performance:
-9.79%
6M Performance:
+39.81%
1Y Performance:
+48.24%
1-Day Range:
$5.6835
$6.25
1-Week Range:
$5.6835
$7.30
52-Week Range:
$2.77
$7.89
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
5.90 | 20.11M | 0 | -14.56M | -12.46M | -16.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Tenax Therapeutics appoints new VP of Clinical Operations - MSN
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving Average – What’s Next? - Defense World
How the (TENX) price action is used to our Advantage - Stock Traders Daily
Leerink Partnrs Weighs in on TENX FY2029 Earnings - Defense World
David Risinger Recommends Buy for Tenax Therapeutics Amid Promising Phase 3 Trials and Growth Potential - TipRanks
Tenax Therapeutics (NASDAQ:TENX) Share Price Passes Above 200-Day Moving Average – What’s Next? - Defense World
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Exclusive: Tenax CEO to Reveal Latest Cardiovascular Drug Pipeline Updates at Major Biotech Conference - StockTitan
Trump's Federal Spending Freeze Puts $3 Trillion In Limbo, Threatens Industries Like Clean Energy, Defense, Health Care - Benzinga
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations - The Manila Times
Analysts Set Tenax Therapeutics, Inc. (NASDAQ:TENX) Target Price at $16.00 - Defense World
PH balance: Tenax outweighs pharmas with levosimendan heart bid - BioWorld Online
Tenax Therapeutics (NASDAQ:TENX) Share Price Crosses Above 200-Day Moving Average – Here’s Why - Defense World
Comparing Merus (NASDAQ:MRUS) & Tenax Therapeutics (NASDAQ:TENX) - Defense World
Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $16.00 Consensus Target Price from Analysts - Defense World
Tenax Therapeutics, Inc. Appoints Thomas A. McGauley as Principal Financial Officer and Principal Accounting Officer - Marketscreener.com
Biotech Soars Following Oversubscribed $100M Private Placement Announcement - MSN
Will Tenax Therapeutics (NASDAQ:TENX) Spend Its Cash Wisely? - Yahoo Finance
Is Tenax Therapeutics (NASDAQ:TENX) In A Good Position To Invest In Growth? - Simply Wall St
Tenax Therapeutics Appoints Interim CFO Thomas McGauley - TipRanks
Tenax Therapeutics: Q3 Earnings Snapshot - New Haven Register
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - The Manila Times
Tenax Therapeutics Secures $100M Funding, Extends Runway to 2027 Despite Wider Q3 Loss | TENX Stock News - StockTitan
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above 200-Day Moving Average – Here’s Why - Defense World
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - The Manila Times
Tenax Therapeutics expands stock incentive plan By Investing.com - Investing.com Australia
Tenax Therapeutics expands stock incentive plan - Investing.com
Tenax Therapeutics Expands Stock Incentive Plan - TipRanks
Analysts Set Tenax Therapeutics, Inc. (NASDAQ:TENX) Target Price at $170.67 - Defense World
FY2024 Earnings Estimate for TENX Issued By Leerink Partnrs - Defense World
Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated at Leerink Partners - Defense World
Leerink Partnrs Upgrades Tenax Therapeutics (NASDAQ:TENX) to “Strong-Buy” - Defense World
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Warning: TENX is at high risk of performing badly - MSN
Guggenheim Initiates Coverage of Tenax Therapeutics (TENX) with Buy Recommendation - Nasdaq
Tenax Therapeutics, Inc. to Post Q3 2024 Earnings of ($1.50) Per Share, William Blair Forecasts (NASDAQ:TENX) - Defense World
William Blair Initiates Coverage of Tenax Therapeutics (TENX) with Outperform Recommendation - MSN
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):